It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Parkinson’s disease (PD) and dementia with Lewy bodies (DLB) are closely related progressive disorders with no available disease-modifying therapy, neuropathologically characterized by intraneuronal aggregates of misfolded α-synuclein. To explore the role of DNA methylation changes in PD and DLB pathogenesis, we performed an epigenome-wide association study (EWAS) of 322 postmortem frontal cortex samples and replicated results in an independent set of 200 donors. We report novel differentially methylated replicating loci associated with Braak Lewy body stage near TMCC2, SFMBT2, AKAP6 and PHYHIP. Differentially methylated probes were independent of known PD genetic risk alleles. Meta-analysis provided suggestive evidence for a differentially methylated locus within the chromosomal region affected by the PD-associated 22q11.2 deletion. Our findings elucidate novel disease pathways in PD and DLB and generate hypotheses for future molecular studies of Lewy body pathology.
Parkinson’s disease and dementia with Lewy bodies are closely related neurodegenerative disorders, although the epigenetic similarities are not well known. Here, the authors study Lewy pathology and DNA methylation in postmortem human frontal cortex, identifying differentially methylated genomic loci.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details





1 Oslo University Hospital, Department of Neurology, Oslo, Norway (GRID:grid.55325.34) (ISNI:0000 0004 0389 8485)
2 University of Exeter Medical School, College of Medicine and Health, University of Exeter, Exeter, UK (GRID:grid.8391.3) (ISNI:0000 0004 1936 8024)
3 Amsterdam Neuroscience, Amsterdam UMC, Vrije Universiteit, Department of Anatomy and Neurosciences, Amsterdam, The Netherlands (GRID:grid.484519.5); Netherlands Brain Bank, Netherlands Institute of Neurosciences, Amsterdam, The Netherlands (GRID:grid.419918.c) (ISNI:0000 0001 2171 8263)
4 Amsterdam Neuroscience, Amsterdam UMC, Vrije Universiteit, Department of Pathology, Amsterdam, The Netherlands (GRID:grid.484519.5)
5 Oslo University Hospital, Department of Neurology, Oslo, Norway (GRID:grid.55325.34) (ISNI:0000 0004 0389 8485); University of Oslo, Institute of Clinical Medicine, Oslo, Norway (GRID:grid.5510.1) (ISNI:0000 0004 1936 8921)
6 Newcastle University, Translational and Clinical Research Institute, Newcastle Upon Tyne, UK (GRID:grid.1006.7) (ISNI:0000 0001 0462 7212)
7 University of Bristol, Dementia Research Group, Bristol Medical School, Bristol, UK (GRID:grid.5337.2) (ISNI:0000 0004 1936 7603)
8 Amsterdam Neuroscience, Amsterdam UMC, Vrije Universiteit, Department of Anatomy and Neurosciences, Amsterdam, The Netherlands (GRID:grid.484519.5)